U.S. FDA extends review of Exelixis' cancer drug
11/09/2026 12:09
U.S. FDA extends review of Exelixis' cancer drug Sept 11 (Reuters) - The U.S. Food and Drug Administration has extended the review of Exelixis' EXEL.O experimental colorectal cancer drug combination by three months, the company said in a filing on Friday.
The regulator will now make its decision by March 3, 2027.
(Reporting by Sriparna Roy in Bengaluru; Editing by Vijay Kishore)